Started in 2008; main approach is based on spraying plants with Agrobac­teria.
Extensive proof of prin­ciple with multiple crops, multiple traits. Several patent applic­a­tions. In search of a stra­tegic partner.

Natural Non-Antibiotic Antibacterials for Food Safety and Healthcare

There is an urgent need in novel antibacterials because of increased antibiotic resistance of human and animal pathogens. Target pathogens for food safety are pathogenic Escherichia coli, Listeria monocytogenes, Salmonella enterica, Clostridium perfringens, Campylobacter spp., etc. Non-antibiotic antimicrobials are known for all target pathogens (colicins, lysins, bacteriocins, etc.), but current production costs are too high and specificities are too narrow.


We propose using plant-made antimicrobial proteins as an alternative to conventional antibiotics. We cloned and successfully expressed over 130 colicins, colicin-like proteins and phage endolysins. We tested them for control of pathogenic Escherichia coli, Listeria, Salmonella, Clostridium, etc. We developed efficacious colicin cocktails against the ‘Big Seven’ STEC coli strains. These data were published in milestone paper in PNAS in Sep 2015.
We obtained excellent results with Salmonella and multidrug resistant E. coli.
Process of manufacturing and storage for colicins was developed; corresponding techno-economic analysis was performed.
First two GRAS application for the US were approved in 2015 and 2017; several GRAS applications are in preparation.

Bioethanol and Industrial Enzymes


Cellulase enzymes account for 30-40% of bioethanol cost-of-goods. For bioethanol production, high tonnage of cellulases is needed to achieve required 1-6% w/w of cellulose residues treated. NOMAD’s technology allows to produce cellulases in green plants at commodity agricultural prices. We expressed over 30 recombinant cellulases and showed them to be active. Silage storage as an intermediate was developed. Proof of concept with inducible transgenic hosts was completed.


NOMAD provides low cost manufacturing solutions. Our manufacturing platforms are broadly applicable. Our platforms allows production of recalcitrant enzymes and other proteins. We developed the process for manufacturing sweet protein thaumatin and received GRAS registration for it.

Healthcare: ICON Genetics subsidiary

  • ICON Genetics was founded in 1999 by Yuri Gleba; the company raised €26 M (equity, debt, grants).
  • ICON was acquired by Bayer in January 2006.
  • 2006-2011, Bayer invested over €100 M in the project:
    – Developed expression processes, including magnICON® technology;
    – Individualized vaccines for Non-Hodgkin Lymphoma (NHL) developed for Bayer;
    – Built GMP-certified manufacturing unit in Halle;
    – Phase I clinical trials with individualized cancer vaccines, completed 2013;
    – ‘Biobetter’ and other product candidates in pre-clinical phase.
  • January 2012, NOMAD acquired ICON from Bayer.
  • January 2013, NOMAD acquired NHL product candidate from Bayer.
  • August 2015, NOMAD sold ICON (but only IP rights to vaccines and diagnostics) to Denka for $85 M.
  • September 2015, NOMAD created Nambawan Biotech GmbH, a wholly owned subsidiary, to continue commercialize healthcare product candidates other than vaccines.

Lysis of Clostridium perfringens NCTC8237 cells with plant-made bacteriophage endolysin psm (3-18 min post treatment). Video by Dr. Vaiva Kazanaviciute, UAB Nomads.